Biocartis Group NV: Biocartis successfully raises EUR 80 million in an equity placement
Summary
We were pleased to see a bookbuilding process that combined solid demand from existing shareholders with strong interest from new local and international institutional investors wanting to invest. Biocartis currently envisages using the net proceeds to fund the expansion of the Idylla(TM) test menu and applications, its sales and marketing activities, the ongoing increase of its cartridge manufacturing capacity, and working capital and other general corporate purposes. This announcement and the information contained herein are not for publication, distribution or release in, or into, the United States, Australia, Canada, Japan, South Africa or any other jurisdiction where to do so would be prohibited by applicable law. No announcement or information regarding the offering, listing or securities of the Company referred to above may be disseminated to the public in jurisdictions where a prior registration or approval is required for such purpose. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development.